{"doi":"10.1101/mcs.a006262","title":"Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma","abstract":"A small percentage of patients have multiple synchronous primary cancers at presentation. In the last five years, many regimens associated with immunotherapy and chemotherapy were approved for first-line metastatic non-small-cell lung cancer (NSCLC) and other solid tumors, but the study of immunotherapy when multiple cancers are present in one patient remains incomplete. Next-generation sequencing biomarkers and immunotherapy markers including PD-L1 can be effectively utilized in the diagnosis and treatment plan for multiple synchronous primary cancers. Immune biomarkers and PD-L1 expression warrant individualized treatments in synchronous primary adenocarcinoma and pulmonary sarcomatoid carcinoma. We describe the case of a patient with pulmonary sarcomatoid carcinoma and lung adenocarcinoma, metastatic to brain de novo. The patient achieved a complete response after only three cycles of carboplatin, paclitaxel, bevacizumab, and atezolizumab and remains free of any evidence of disease after 18 mo of maintenance therapy.","journal":"Molecular Case Studies","year":2023,"id":396368,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9468,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":317443,"name":"Isa Mambetsariev","orcid":"0000-0003-2882-0249","position":1,"is_corresponding":false},{"id":317444,"name":"Jeremy Fricke","orcid":"0000-0003-4684-8114","position":2,"is_corresponding":false},{"id":582368,"name":"Daniel Schmolze","orcid":"0000-0002-6947-2546","position":3,"is_corresponding":false},{"id":780091,"name":"Michelle Afkhami","orcid":"0000-0001-5830-6158","position":4,"is_corresponding":false},{"id":414124,"name":"Rifat Mannan","orcid":"0000-0003-1735-7770","position":5,"is_corresponding":false},{"id":73180,"name":"Pauline Kim","orcid":null,"position":6,"is_corresponding":false},{"id":950716,"name":"Shaira Therese Dingal","orcid":null,"position":7,"is_corresponding":false},{"id":1172251,"name":"Bao Gia Nguyen","orcid":null,"position":8,"is_corresponding":false},{"id":1077437,"name":"Razmig Babikian","orcid":null,"position":9,"is_corresponding":false},{"id":337777,"name":"Yuman Fong","orcid":"0000-0002-8934-9959","position":10,"is_corresponding":false},{"id":108575,"name":"Ravi Salgia","orcid":"0000-0001-9643-7626","position":11,"is_corresponding":false},{"id":507004,"name":"Diogo Moniz‐Garcia","orcid":"0000-0002-3654-3387","position":0,"is_corresponding":true}],"reference_count":58,"raw_metadata":null,"created_at":"2026-07-19T01:19:31.472087Z","pmid":"37160318","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}